| Person in charge of the project: |
Construction and characterization of antibody fragments against Thrombim Activatable Fibrinolysis Inhibitor (TAFI).
|
|
The proenzyme thrombin activatable fibrinolysis inhibitor (TAFI) can be activated to the active enzyme TAFIa by trypsin-like enzymes. TAFIa exerts an antifibrinolytic effect by removing C-terminal lysine residues from fibrin, resulting in a decreased plasmin formation. Plasminogen activator inhibitor 1 (PAI-1) is the main physiological inhibitor of tissue type plasminogen activator. Both proteins delay the formation of plasmin. A bispecific diabodies are antibodies that can target two proteins simultaneously. The aim of this project is to generate a bispecific diabody as a new thrombolyticum. The project contains the following objectives: 1) Construction and characterization of antibody fragments of monoclonal antibodies that can inhibit TAFI; 2) Simultaneous inhibition of TAFI and PAI-1 through a bispecific diabody.
|
| |
Project number:
3M050223
Duration of the project:
01.10.2005 - 27.09.2009
Funded research
Nederlands
|
